BIO3 Share Price

Open 21.06 Change Price %
High 21.28 1 Day 0.00 0.00
Low 20.80 1 Week 1.44 7.29
Close 21.20 1 Month 1.49 7.56
Volume 96190 1 Year 5.35 33.75
52 Week High 21.60
52 Week Low 12.02
BIO3 Important Levels
Resistance 2 21.64
Resistance 1 21.46
Pivot 21.09
Support 1 20.94
Support 2 20.76
ETR Germany Most Active Stocks
DTE 17.95 0.22%
DTE 17.95 0.22%
DTE 17.95 0.22%
DTE 17.95 0.22%
DTE 17.95 0.22%
EOAN 7.55 0.13%
EOAN 7.55 0.13%
CBK 9.35 -0.32%
CBK 9.35 -0.32%
DBK 16.43 -0.36%
More..
ETR Germany Top Gainers Stocks
S9H 0.16 45.45%
MLL 8.85 17.22%
OBS 6.95 13.93%
OBS 6.95 13.93%
5M71 39.00 13.70%
VSC 3.95 12.86%
VSC 3.95 12.86%
PV3 2.09 11.76%
TGT 0.90 11.11%
TGT 0.90 11.11%
More..
ETR Germany Top Losers Stocks
MPI 0.25 -98.98%
MPI 0.25 -98.98%
APL 2.60 -34.18%
APL 2.60 -34.18%
APL 2.60 -34.18%
EMQ 0.02 -33.33%
SMK 0.04 -20.00%
ZSB 0.10 -9.09%
SFD1 5.96 -7.17%
I7N 1.60 -6.98%
More..

Biotest AG (ETR: BIO3)

BIO3 Technical Analysis 5
As on 29th May 2017 BIO3 Share Price closed @ 21.20 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 15.24 & Strong Buy for SHORT-TERM with Stoploss of 19.20 we also expect STOCK to react on Following IMPORTANT LEVELS.
BIO3 Target for May
1st Target up-side 21.15
2nd Target up-side 22.16
3rd Target up-side 23.17
1st Target down-side 18.27
2nd Target down-side 17.26
3rd Target down-side 16.25
BIO3 Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.biotest.de
BIO3 Address
BIO3
Landsteinerstrasse 5
Dreieich, 63303
Germany
Phone: 49 6103 801 4406
Fax: 49 6103 801 347
BIO3 Latest News
Interactive Technical Analysis Chart Biotest AG ( BIO3 ETR Germany )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Biotest AG
BIO3 Business Profile
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological medicinal products worldwide. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin for haemophilia A acute therapy and prophylaxis; Haemonine for haemophilia B acute therapy and prophylaxis; Bivigam for primary immune deficiency; Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect CP for hepatitis B re-infection prophylaxis; Intratect for primary immune deficiency and secondary antibody deficiency syndromes, as well as autoimmune diseases; Nabi-HB for prophylaxis of hepatitis B virus infection; Varitect CP for zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. The company also provides Albiomin for volume depletion; Biseko for the deficiency of volume and serum proteins; Cofact for the deficiency of clotting factors; Humanalbumin for volume depletion; and Pentaglobin for the treatment of severe bacterial infections. In addition, its products under development include Indatuximab Ravtansine (BT-062) for multiple myeloma and solid tumors; BT-063 for the treatment of systemic lupus erythematosus; BT-094 (Cytotect 70) for the treatment of congenital cytomegalovirus infections; Civacir for the treatment of hepatitis C infection; Tregalizumab (BT-061) for the treatment of rheumatoid arthritis and psoriasis; Fibrinogen for the deficiency of fibrinogen; and IgM concentrate for severe bacterial infections. Biotest Aktiengesellschaft has a collaboration agreement with AbbVie for the development of monoclonal antibody BT-061. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany.